Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer

Abstract This study evaluates the cost-effectiveness of adding durvalumab to chemotherapy, with subsequent maintenance either with olaparib (DOCT) or without olaparib (DCT), versus chemotherapy alone (CT) as a first-line treatment for advanced endometrial cancer (EC) in the United States, stratified...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiahao Zhang, Jianying Lei, Caicong You, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Durvalumab
Olaparib
Advanced endometrial cancer
Cost-effectiveness
Online Access:https://doi.org/10.1038/s41598-025-86021-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-86021-y

Similar Items